Augmenix Inc. showcased the SpaceOAR System at the 57th annual American Society of Therapeutic Radiology and Oncology meeting, highlighting robust commercial uptake in the United States. An absorbable hydrogel, SpaceOAR technology is designed to create space and protect the rectum in men undergoing prostate cancer radiotherapy. The device received clearance from the U.S. Food and Drug Administration (FDA) in April 2015 and since then, more than 40 cancer treatment centers in 19 states have adopted it.

The AeroDR LT is a smart wireless digital radiography (DR) solution that can be used in most rooms and portable X-ray systems. The flat panel detector delivers added economic value by extending the life and value of existing radiology rooms and solutions. AeroDR LT is easy to carry and easy to position with its light weight (5.5 lbs.) and grip strips right on the panel—helping increase both patient satisfaction and technologist productivity.

Mach7 Technologies and 3D Medical Limited announced yesterday they have signed a definitive agreement to merge together. The merger will provide access via public capital markets for Mach7 while preserving corporate self-determination with regard to mission and product roadmap. Upon approval and completion of the agreement, the merged entity will be publicly listed on the Australian stock exchange (ASX) and will trade as "Mach7 Technologies Ltd."

New data from clinical trials conducted at Penn Medicine’s Robert Proton Therapy Center demonstrate the technology's potential advantages over conventional radiation, including less side effects and survival in some cases, for several harder-to-treat tumors. This includes pancreatic, late-stage non-small cell lung and chordoma and chondrosarcoma, two rare cancers found in bone or soft tissue.

Patients with intermediate meningiomas treated with radiation therapy (RT) after surgery experienced a 96 percent three-year progression-free survival rate and had minimal adverse events, according to new research. Study findings were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy (RT) targeting only the involved lymph nodes regions results in less toxicity without causing a statistically significant difference in loco-regional lymph nodal recurrence, distant failure and overall survival rates, according to new research. Study findings were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

Outcomes for pediatric patients as young as 12 months with ependymoma who are treated with immediate post-operative radiation therapy are favorable and consistent based upon the patients’ tumor surgical resection and tumor grade, according to new research. Findings from the study were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

Bracco Diagnostics Inc. announced that Lumason was approved by the Centers for Medicare and Medicaid Services (CMS) for pass-through status under the Hospital Outpatient Prospective Payment System (HOPPS). Lumason is an ultrasound contrast agent indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.